<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALTREXÂ - valacyclovir hydrochlorideÂ tablet, film coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VALTREX safely and effectively. See full prescribing information for VALTREX.<br>Â <br>VALTREX (valacyclovir hydrochloride) Caplets<br>Initial U.S. Approval: 1995</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for:  (<a href="#section-1">1</a>)</p>
<p class="Highlighta"><span class="Underline">Adult Patients (1.1)</span>  (<a href="#section-1">1</a>)</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span><ul>
<li>Treatment in immunocompetent patients (initial or recurrent episode)</li>
<li>Suppression in immunocompetent or HIV-1 infected patients</li>
<li>Reduction of transmission</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></li>
</ul>
<p class="Highlighta"><span class="Underline">Pediatric Patients (1.2)</span>  (<a href="#section-1">1</a>)</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></li>
</ul>
<p class="Highlighta"><span class="Underline">Limitations of Use (1.3)</span>  (<a href="#section-1">1</a>)</p>
<ul><li>The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-1 infected patients.</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="id_7ac78d60-fc3e-4d5a-83f3-7734b3ec61ca"></a><table>
<col width="46.4%">
<col width="53.6%">
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Adult Dosage</span> (2.1)</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span></td>
<td class="Botrule" align="left" valign="top">2Â grams every 12Â hours for 1Â day</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> </td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Initial episode</td>
<td class="Botrule" align="left" valign="top">1Â gram twice daily for 10Â days</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Recurrent episodes</td>
<td class="Botrule" align="left" valign="top">500Â mg twice daily for 3Â days</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Suppressive therapy </td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Immunocompetent patients</td>
<td align="left" valign="top">1Â gram once daily </td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Alternate dose in patients with less than or equal to 9Â recurrences/year</td>
<td align="left" valign="top">500Â mg once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">HIV-1 infected patients</td>
<td class="Botrule" align="left" valign="top">500Â mg twice daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Reduction of transmission</td>
<td class="Botrule" align="left" valign="top">500Â mg once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></td>
<td class="Botrule" align="left" valign="top">1Â gram 3 times daily for 7Â days</td>
</tr>
<tr><td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Pediatric Dosage</span> (2.2)</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (aged greater than or equal to 12 years)</td>
<td class="Botrule" align="left" valign="top">2 grams every 12Â hours for 1Â day</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> (aged 2 to less than 18Â years)</td>
<td align="left" valign="top">20Â mg/kg 3Â times daily for 5Â days; not to exceed 1Â gram 3Â times daily</td>
</tr>
</tbody>
</table>
<p class="Highlighta">Valacyclovir oral suspension (25Â mg/mL or 50Â mg/mL) can be prepared from the 500Â mg VALTREX Caplets. (2.3)  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Caplets: 500Â mg (unscored), 1Â gram (partially scored) (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to valacyclovir (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), acyclovir, or any component of the formulation. (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8Â grams per day of VALTREX in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. (5.1)</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>: May occur in elderly patients (with or without reduced renal function), patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who receive higher than recommended doses of VALTREX for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (2.4, 5.2)</li>
<li>Central nervous system adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who receive higher than recommended doses of VALTREX for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (2.4, 5.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul>
<li>The most common adverse reactions reported in at least one indication by greater than 10% of adult patients treated with VALTREX and more commonly than in patients treated with placebo are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (6.1)</li>
<li>The only adverse reaction occurring in greater than 10% of pediatric patients less than 18Â years of age was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (6.2)<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adult Patients</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Pediatric Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Dosing Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Dosing Recommendations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Extemporaneous Preparation of Oral Suspension</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (TTP/HUS)</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Central Nervous System Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Patients</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience in Pediatric Patients</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Infections</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></a></h2>
<h2><a href="#section-13.4" class="toc">14.4 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Importance of Adequate Hydration</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></a></h2>
<h2><a href="#section-15.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_87e80c99-b91b-4a49-9f52-c4c18665a61a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_934c96cf-4ed4-4ce4-b9a7-c1d22b903190"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adult Patients</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> VALTREX<span class="Sup">Â®</span> (valacyclovir hydrochloride) Caplets are indicated for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>). The efficacy of VALTREX initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>) has not been established.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics"> Initial Episode: </span>VALTREX is indicated for treatment of the initial episode of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 72Â hours after the onset of signs and symptoms has not been established.</p>
<p><span class="Italics">Recurrent Episodes: </span>VALTREX is indicated for treatment of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 24Â hours after the onset of signs and symptoms has not been established.</p>
<p><span class="Italics">Suppressive Therapy: </span>VALTREX is indicated for chronic suppressive therapy of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent and in HIV-1 infected adults. The efficacy and safety of VALTREX for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> beyond 1Â year in immunocompetent patients and beyond 6Â months in HIV-1 infected patients have not been established.</p>
<p><span class="Italics">Reduction of Transmission: </span>VALTREX is indicated for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of VALTREX for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> beyond 8Â months in discordant couples has not been established. The efficacy of VALTREX for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] <span class="Italics"><span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span> Treatment Guidelines</span>).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> VALTREX is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>) in immunocompetent adults. The efficacy of VALTREX when initiated more than 72Â hours after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and the efficacy and safety of VALTREX for treatment of disseminated <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_109d944f-bbd6-4321-af8d-98ca43218956"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Pediatric Patients</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> VALTREX is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>) in pediatric patients aged greater than or equal to 12Â years. The efficacy of VALTREX initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>) has not been established.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</span> VALTREX is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in immunocompetent pediatric patients aged 2 to less than 18Â years. Based on efficacy data from clinical studies with oral acyclovir, treatment with VALTREX should be initiated within 24Â hours after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see Clinical Studies (14.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a719c17-7b59-4af9-9d53-4fe660865026"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">The efficacy and safety of VALTREX have not been established in:</p>
<ul>
<li>Immunocompromised patients other than for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-1 infected patients with a CD4+ cell count greater than or equal to 100Â cells/mm<span class="Sup">3</span>.</li>
<li>Patients aged less than 12Â years with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>).</li>
<li>Patients aged less than 2Â years or greater than or equal to 18Â years with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>.</li>
<li>Patients aged less than 18Â years with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
<li>Patients aged less than 18Â years with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>.</li>
<li>Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_593776af-c1d9-45ae-8b83-0a050d0bd39d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<ul>
<li>VALTREX may be given without regard to meals.</li>
<li>Valacyclovir oral suspension (25Â mg/mL or 50Â mg/mL) may be prepared extemporaneously from 500Â mg VALTREX Caplets for use in pediatric patients for whom a solid dosage form is not appropriate <span class="Italics">[see Dosage and Administration (2.3)]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ddf78bb-69ca-4234-89dc-3a28697201b4"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Dosing Recommendations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> The recommended dosage of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> is 2Â grams twice daily for 1Â day taken 12Â hours apart. Therapy should be initiated at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics"> Initial Episode: </span>The recommended dosage of VALTREX for treatment of initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 1Â gram twice daily for 10Â days. Therapy was most effective when administered within 48Â hours of the onset of signs and symptoms.</p>
<p><span class="Italics">Recurrent Episodes: </span>The recommended dosage of VALTREX for treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 500Â mg twice daily for 3Â days. Initiate treatment at the first sign or symptom of an episode.</p>
<p><span class="Italics">Suppressive Therapy:</span> The recommended dosage of VALTREX for chronic suppressive therapy of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 1Â gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500Â mg once daily.</p>
<p>In HIV-1 infected patients with a CD4+ cell count greater than or equal to 100Â cells/mm<span class="Sup">3</span>, the recommended dosage of VALTREX for chronic suppressive therapy of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 500Â mg twice daily.</p>
<p><span class="Italics">Reduction of Transmission:</span> The recommended dosage of VALTREX for reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in patients with a history of 9 or fewer recurrences per year is 500Â mg once daily for the source partner.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> The recommended dosage of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> is 1Â gram 3Â times daily for 7Â days. Therapy should be initiated at the earliest sign or symptom of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> and is most effective when started within 48Â hours of the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6094aa52-378c-411f-b80b-eb578244d1f6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Dosing Recommendations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> The recommended dosage of VALTREX for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> in pediatric patients aged greater than or equal to 12Â years is 2Â grams twice daily for 1Â day taken 12Â hours apart. Therapy should be initiated at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</span> The recommended dosage of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in immunocompetent pediatric patients aged 2 to less than 18Â years is 20Â mg/kg administered 3Â times daily for 5Â days. The total dose should not exceed 1Â gram 3Â times daily. Therapy should be initiated at the earliest sign or symptom <span class="Italics">[see Use in Specific Populations (8.4), Clinical Pharmacology (12.3), Clinical Studies (14.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6385a9db-463a-4d4d-98a7-6d92a9ec1d58"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Extemporaneous Preparation of Oral Suspension</h2>
<p class="First"><span class="Underline">Ingredients and Preparation per USP-NF:</span> VALTREX Caplets 500Â mg, cherry flavor, and Suspension Structured Vehicle USP-NF (SSV). Valacyclovir oral suspension (25Â mg/mL or 50Â mg/mL) should be prepared in lots of 100Â mL.</p>
<p><span class="Underline">Prepare Suspension at Time of Dispensing as Follows:</span></p>
<ul>
<li>Prepare SSV according to the USP-NF.</li>
<li>Using a pestle and mortar, grind the required number of VALTREX 500Â mg Caplets until a fine powder is produced (5Â VALTREX Caplets for 25Â mg/mL suspension; 10Â VALTREX Caplets for 50Â mg/mL suspension).</li>
<li>Gradually add approximately 5Â mL aliquots of SSV to the mortar and triturate the powder until a paste has been produced. Ensure that the powder has been adequately wetted.</li>
<li>Continue to add approximately 5Â mL aliquots of SSV to the mortar, mixing thoroughly between additions, until a concentrated suspension is produced, to a minimum total quantity of 20Â mL SSV and a maximum total quantity of 40Â mL SSV for both the 25Â mg/mL and 50Â mg/mL suspensions.</li>
<li>Transfer the mixture to a suitable 100Â mL measuring flask.</li>
<li>Transfer the cherry flavor* to the mortar and dissolve in approximately 5Â mL of SSV. Once dissolved, add to the measuring flask.</li>
<li>Rinse the mortar at least 3Â times with approximately 5Â mL aliquots of SSV, transferring the rinsing to the measuring flask between additions.</li>
<li>Make the suspension to volume (100Â mL) with SSV and shake thoroughly to mix.</li>
<li>Transfer the suspension to an amber glass medicine bottle with a child-resistant closure.</li>
<li>The prepared suspension should be labeled with the following information â€œShake well before using. Store suspension between 2Â° to 8Â°C (36Â° to 46Â°F) in a refrigerator. Discard after 28Â days.â€?</li>
</ul>
<p>* The amount of cherry flavor added is as instructed by the suppliers of the cherry flavor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b971c354-7721-4b71-b5b0-a991b1c2c5dc"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage recommendations for adult patients with reduced renal function are provided in TableÂ 1 <span class="Italics">[see Use in Specific Populations (8.5, 8.6), Clinical Pharmacology (12.3)]</span>. Data are not available for the use of VALTREX in pediatric patients with a creatinine clearance less than 50Â mL/min/1.73Â m<span class="Sup">2</span>.</p>
<a name="id_b52f2966-b8bf-456b-8c19-35e00840078a"></a><table width="615.000">
<caption><span>Table 1. VALTREX Dosage Recommendations for Adults With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col width="28.6%">
<col width="17.9%">
<col width="16.9%">
<col width="16.9%">
<col width="19.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Indications</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">Normal Dosage Regimen (Creatinine ClearanceÂ â‰¥50Â mL/min)</td>
<td class="Botrule" align="center" colspan="3" valign="bottom">Creatinine Clearance (mL/min)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">30-49</td>
<td class="Botrule Rrule" align="center" valign="bottom">10-29</td>
<td class="Botrule" align="center" valign="bottom">&lt;10</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span>)</span></p>
<p>Â </p>
<span class="Bold">Do not exceed 1Â day of treatment.</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Two 2Â gram doses taken 12Â hours apart</td>
<td class="Botrule Rrule" align="center" valign="top">Two 1Â gram doses taken 12Â hours apart</td>
<td class="Botrule Rrule" align="center" valign="top">Two 500Â mg doses taken 12Â hours apart</td>
<td class="Botrule" align="center" valign="top">500Â mg single dose</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>: </span></p>
<span class="Bold">Â Initial episode</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1Â gram every 12Â hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">1Â gram every 24Â hours</td>
<td class="Botrule" align="center" valign="top">500Â mg every 24Â hours</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>: </span></p>
<span class="Bold">Â Recurrent episode</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">500Â mg every 12Â hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">500Â mg every 24Â hours</td>
<td class="Botrule" align="center" valign="top">500Â mg every 24Â hours</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>: </span></p>
<span class="Bold">Â Suppressive therapy</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<p class="First">Â Â Â Immunocompetent patients</p>
<p>Â </p>
</td>
<td class="Rrule" align="center" valign="top">1Â gram every 24Â hours</td>
<td class="Rrule" align="center" valign="top">no reduction</td>
<td class="Rrule" align="center" valign="top">500Â mg every 24Â hours</td>
<td align="center" valign="top">500Â mg every 24Â hours</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<p class="First">Â Â Â Alternate dose for immunocompetent patients with greater than or equal to 9Â recurrences/year</p>
<p>Â </p>
</td>
<td class="Rrule" align="center" valign="top">500Â mg every 24Â hours</td>
<td class="Rrule" align="center" valign="top">no reduction</td>
<td class="Rrule" align="center" valign="top">500Â mg every 48Â hours</td>
<td align="center" valign="top">500Â mg every 48Â hours</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â HIV-1 infected patients</td>
<td class="Botrule Rrule" align="center" valign="top">500Â mg every 12Â hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">500Â mg every 24Â hours</td>
<td class="Botrule" align="center" valign="top">500Â mg every 24Â hours</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span></span></td>
<td class="Rrule" align="center" valign="top">1Â gram every 8Â hours</td>
<td class="Rrule" align="center" valign="top">1Â gram every 12Â hours</td>
<td class="Rrule" align="center" valign="top">1Â gram every 24Â hours</td>
<td class="Botrule" align="center" valign="top">500Â mg every 24Â hours</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Hemodialysis:</span> Patients requiring hemodialysis should receive the recommended dose of VALTREX after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of VALTREX is approximately 4Â hours. About one third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session.</p>
<p><span class="Underline">Peritoneal Dialysis:</span> There is no information specific to administration of VALTREX in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) not receiving hemodialysis. Therefore, supplemental doses of VALTREX should not be required following CAPD or CAVHD.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_44b99ca3-59ea-4ee2-8592-189aad1945f4"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Caplets:</p>
<ul>
<li>500-mg: blue, film-coated, capsule-shaped tablets printed with "VALTREX 500Â mg."</li>
<li>1-gram:Â  blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides, printed with "VALTREX 1Â gram."</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_9e25f43c-04aa-4484-aac9-8477cf77c7fa"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">VALTREX is contraindicated in patients who have had a demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to valacyclovir, acyclovir, or any component of the formulation <span class="Italics">[see Adverse Reactions (6.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_39abc10c-ab9c-4268-ac93-270324edc885"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b1b91c9-ec5a-4d12-af7d-3594154867c7"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (TTP/HUS)</h2>
<p class="First">TTP/HUS, in some cases resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has occurred in patients with advanced HIV-1 disease and also in allogeneic bone marrow transplant and renal transplant recipients participating in clinical trials of VALTREX at doses of 8Â grams per day. Treatment with VALTREX should be stopped immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_644888b0-6634-434d-976f-b940ef194b7b"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported in:</p>
<ul>
<li>Elderly patients with or without reduced renal function. Caution should be exercised when administering VALTREX to geriatric patients, and dosage reduction is recommended for those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see Dosage and Administration (2.4), Use in Specific Populations (8.5)].</span>
</li>
<li>Patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who received higher than recommended doses of VALTREX for their level of renal function. Dosage reduction is recommended when administering VALTREX to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (2.4), Use in Specific Populations (8.6)].</span>
</li>
<li>Patients receiving other nephrotoxic drugs. Caution should be exercised when administering VALTREX to patients receiving potentially nephrotoxic drugs.</li>
<li>Patients without adequate hydration. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5Â mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients.</li>
</ul>
<p>In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored <span class="Italics">[see Dosage and Administration (2.4), Adverse Reactions (6.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e72f217c-663b-4f8b-b064-43f2f35b0b14"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Central Nervous System Effects</h2>
<p class="First">Central nervous system adverse reactions, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, have been reported in both adult and pediatric patients with or without reduced renal function and in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who received higher than recommended doses of VALTREX for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. VALTREX should be discontinued if central nervous system adverse reactions occur <span class="Italics">[see Adverse Reactions (6.3), Use in Specific Populations (8.5, 8.6)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ef81a020-e936-4405-874c-12f5dea1e910"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/HemolyticÂ  <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Uremic Syndrome</span> <span class="Italics">[see Warnings and Precautions (5.1)].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</li>
<li>Central Nervous System Effects <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</li>
</ul>
<p>The most common adverse reactions reported in at least 1Â indication by greater than 10% of adult patients treated with VALTREX and observed more frequently with VALTREX compared to placebo are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. The only adverse reaction reported in greater than 10% of pediatric patients aged less than 18Â years was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e67af8d-3ffb-4a61-8156-00eeba542b84"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Patients</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> In clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, the adverse reactions reported by patients receiving VALTREX 2Â grams twice daily (nÂ =Â 609) or placebo (nÂ =Â 609) for 1Â day, respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%, 10%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2%, 1%). The frequencies of abnormal ALT (greater than 2 x ULN) were 1.8% for patients receiving VALTREX compared with 0.8% for placebo. Other laboratory abnormalities (hemoglobin, white blood cells, alkaline phosphatase, and serum creatinine) occurred with similar frequencies in the 2Â groups.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics"> Initial Episode: </span>In a clinical study for the treatment of initial episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by greater than or equal to 5% of patients receiving VALTREX 1Â gram twice daily for 10Â days (nÂ =Â 318) or oral acyclovir 200Â mg 5Â times daily for 10Â days (nÂ =Â 318), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%, 10%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (6%, 6%). For the incidence of laboratory abnormalities see TableÂ 2.</p>
<p><span class="Italics">Recurrent Episodes: </span>In 3 clinical studies for the episodic treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by greater than or equal to 5% of patients receiving VALTREX 500Â mg twice daily for 3Â days (nÂ =Â 402), VALTREX 500Â mg twice daily for 5Â days (nÂ =Â 1,136) or placebo (nÂ =Â 259), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (16%, 11%, 14%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%, 4%, 5%). For the incidence of laboratory abnormalities see TableÂ 2.</p>
<p><span class="Italics">Suppressive Therapy: Suppression of Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in Immunocompetent Adults: </span>In a clinical study for the suppression of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> infections, the adverse reactions reported by patients receiving VALTREX 1Â gram once daily (nÂ =Â 269), VALTREX 500Â mg once daily (nÂ =Â 266), or placebo (nÂ =Â 134), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (35%, 38%, 34%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11%, 11%, 8%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (11%, 9%, 6%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (8%, 5%, 4%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (7%, 5%, 5%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6%, 5%, 4%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%, 3%, 2%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (4%, 2%, 1%). For the incidence of laboratory abnormalities see TableÂ 2.</p>
<p><span class="Italics">Suppression of Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in HIV-1 Infected Patients: </span>In HIV-1 infected patients, frequently reported adverse reactions for VALTREX (500Â mg twice daily; nÂ =Â 194, median days on therapyÂ =Â 172) and placebo (nÂ =Â 99, median days on therapyÂ =Â 59), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%, 8%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (8%, 5%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (8%, 1%). Post-randomization laboratory abnormalities that were reported more frequently in valacyclovir subjects versus placebo included elevated alkaline phosphatase (4%, 2%), elevated ALT (14%, 10%), elevated AST (16%, 11%), decreased neutrophil counts (18%, 10%), and decreased platelet counts (3%, 0%), respectively.</p>
<p><span class="Italics">Reduction of Transmission: </span>In a clinical study for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by patients receiving VALTREX 500Â mg once daily (nÂ =Â 743) or placebo once daily (nÂ =Â 741), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (29%, 26%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (16%, 15%), and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (9%, 10%).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> In 2Â clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, the adverse reactions reported by patients receiving VALTREX 1Â gram 3Â times daily for 7 to 14Â days (nÂ =Â 967) or placebo (nÂ =Â 195), respectively, included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (15%, 8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%, 12%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6%, 3%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3%, 2%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3%, 2%). For the incidence of laboratory abnormalities see TableÂ 2.</p>
<a name="id_68437375-ee5b-4f3a-a1b6-4dc54b101778"></a><table width="631.000">
<caption><span>Table 2. Incidence (%) of Laboratory Abnormalities in <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> and <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Study Populations</span></caption>
<col width="25.2%">
<col width="8.7%">
<col width="7.8%">
<col width="8.7%">
<col width="8.7%">
<col width="8.7%">
<col width="11.3%">
<col width="10.5%">
<col width="10.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Laboratory Abnormality</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Treatment</td>
<td class="Botrule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Suppression</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX</p>
<p>1Â gram</p>
<p>3Â times daily</p>(nÂ =Â 967)</td>
<td class="Botrule Rrule" align="justify" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 195)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX </p>
<p>1Â gram twice daily</p>(nÂ =Â 1,194)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX</p>
<p>500Â mg twice daily</p>(nÂ =Â 1,159)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 439)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX</p>
<p>1Â gram once daily</p>(nÂ =Â 269)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX</p>
<p>500Â mg once daily</p>(nÂ =Â 266)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 134)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Hemoglobin </p>(&lt;0.8 x LLN)</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule" align="center" valign="top">0.8%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">White blood cells</p>(&lt;0.75 x LLN)</td>
<td class="Botrule Rrule" align="center" valign="top">1.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%</td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule" align="center" valign="top">1.5%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Platelet count (&lt;100,000/mm<span class="Sup">3</span>) </td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top">1.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.1%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.4%</td>
<td class="Botrule Rrule" align="center" valign="top">1.1%</td>
<td class="Botrule" align="center" valign="top">1.5%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</p>(&gt;2 x ULN)</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Sup">a</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.5%</td>
<td class="Botrule Rrule" align="center" valign="top">4.1%</td>
<td class="Botrule Rrule" align="center" valign="top">3.8%</td>
<td class="Botrule" align="center" valign="top">3.0%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Serum creatinine</p>(&gt;1.5 x ULN) </td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule" align="center" valign="top">0%</td>
</tr>
<tr><td align="left" colspan="9" valign="top">
<span class="Sup">a</span> Data were not collected prospectively.</td></tr>
<tr><td align="left" colspan="9" valign="top">LLN = Lower limit of normal.</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="9" valign="top">ULN = Upper limit of normal.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df3f9eae-8090-4458-a518-7b8cf27c3ddb"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience in Pediatric Patients</h2>
<p class="First">The safety profile of VALTREX has been studied in 177 pediatric patients aged 1Â month to less than 18Â years. Sixty-five of these pediatric patients, aged 12 to less than 18Â years, received oral caplets for 1 to 2Â days for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. The remaining 112Â pediatric patients, aged 1Â month to less than 12Â years, participated in 3 pharmacokinetic and safety studies and received valacyclovir oral suspension. Fifty-one of these 112Â pediatric patients received oral suspension for 3 to 6Â days. The frequency, intensity, and nature of clinical adverse reactions and laboratory abnormalities were similar to those seen in adults.</p>
<p><span class="Underline">Pediatric Patients Aged 12 to Less Than 18Â Years (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>):</span> In clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, the adverse reactions reported by adolescent patients receiving VALTREX 2Â grams twice daily for 1Â day, or VALTREX 2Â grams twice daily for 1Â day followed by 1Â gram twice daily for 1Â day (nÂ =Â 65, across both dosing groups), or placebo (nÂ =Â 30), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17%, 3%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (8%, 0%).</p>
<p><span class="Underline">Pediatric Patients Aged 1 Month to Less Than 12Â Years:</span> Adverse events reported in more than 1Â subject across the 3Â pharmacokinetic and safety studies in children aged 1Â month to less than 12Â years were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (4%), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (2%), herpes simplex (2%), and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (2%). No clinically meaningful changes in laboratory values were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c661f70d-0fe0-42b0-82b1-cbbdbe2a69c2"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of VALTREX. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to VALTREX.</p>
<p><span class="Underline">General:</span> Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Underline">Allergic:</span> Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> <span class="Italics">[see Contraindications (4)]</span>.</p>
<p><span class="Underline">CNS Symptoms:</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span>; <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; decreased consciousness; <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>; <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>; <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>; and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, including auditory and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span><span class="Italics"> [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), (8.6)].</span></p>
<p><span class="Underline">Eye:</span> Visual abnormalities.</p>
<p><span class="Underline">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</p>
<p><span class="Underline">Hepatobiliary Tract and Pancreas:</span> Liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Underline">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span> (may be associated with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) <span class="Italics">[see Warnings and Precautions (5.2), Use in Specific Populations (8.5), (8.6)]</span>.</p>
<p><span class="Underline">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, TTP/HUS <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Underline">Skin:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> including <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_37003dee-ee30-4c21-8470-a16bef282eba"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No clinically significant drug-drug or drug-food interactions with VALTREX are known <span class="Italics">[see Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_079b84e1-ffff-4af5-b960-df171407f5f6"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5444f4f2-866f-45d5-9efe-dcb52bbaa697"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. There are no adequate and well-controlled studies of VALTREX or acyclovir in pregnant women. Based on prospective pregnancy registry data on 749Â pregnancies, the overall rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in infants exposed to acyclovir in-utero appears similar to the rate for infants in the general population. VALTREX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in AprilÂ 1999. There were 749Â pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756Â outcomes. The occurrence rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.</p>
<p>Animal reproduction studies performed at oral doses that provided up to 10Â and 7Â times the human plasma levels during the period of major organogenesis in rats and rabbits, respectively, revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_b27a88d6-3337-46b7-b688-0ba73ed4ca78"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Following oral administration of a 500Â mg dose of VALTREX to 5Â nursing mothers, peak acyclovir concentrations (C<span class="Sub">max</span>) in breast milk ranged from 0.5Â to 2.3Â times (median 1.4) the corresponding maternal acyclovir serum concentrations. The acyclovir breast milk AUC ranged from 1.4Â to 2.6Â times (median 2.2) maternal serum AUC. A 500Â mg maternal dosage of VALTREX twice daily would provide a nursing infant with an oral acyclovir dosage of approximately 0.6Â mg/kg/day. This would result in less than 2% of the exposure obtained after administration of a standard neonatal dose of 30Â mg/kg/day of intravenous acyclovir to the nursing infant. Unchanged valacyclovir was not detected in maternal serum, breast milk, or infant urine. Caution should be exercised when VALTREX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1bf9118c-3446-4bd4-b4b3-665d15bb8f5b"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">VALTREX is indicated for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> in pediatric patients aged greater than or equal to 12Â years and for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients aged 2Â to less than 18Â years <span class="Italics">[see Indications and Usage (1.2), Dosage and Administration (2.2)]</span>.</p>
<p> The use of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> is based on 2Â double-blind, placebo-controlled clinical trials in healthy adults and adolescents (aged greater than or equal to 12Â years) with a history of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> <span class="Italics">[see Clinical Studies (14.1)]</span>.</p>
<p> The use of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients aged 2 to less than 18Â years is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by efficacy and safety data from 3Â randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> <span class="Italics">[see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]</span>.</p>
<p> The efficacy and safety of valacyclovir have not been established in pediatric patients:</p>
<ul>
<li>aged less than 12Â years with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span></li>
<li>aged less than 18Â years with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span></li>
<li>aged less than 18Â years with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span></li>
<li>aged less than 2Â years with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span></li>
<li>for suppressive therapy following neonatal HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p>The pharmacokinetic profile and safety of valacyclovir oral suspension in children aged less than 12Â years were studied in 3 open-label studies. No efficacy evaluations were conducted in any of the 3Â studies.</p>
<p>Study 1 was a single-dose pharmacokinetic, multiple-dose safety study in 27Â pediatric patients aged 1 to less than 12Â years with clinically suspected <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus (VZV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)].</span></p>
<p>Study 2 was a single-dose pharmacokinetic and safety study in pediatric patients aged 1Â month to less than 6Â years who had an active <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infection</span> or who were at risk for <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infection</span>. Fifty-seven subjects were enrolled and received a single dose of 25Â mg/kg valacyclovir oral suspension. In infants and children aged 3Â months to less than 6Â years, this dose provided comparable systemic acyclovir exposures to that from a 1-gram dose of valacyclovir in adults (historical data). In infants aged 1Â month to less than 3Â months, mean acyclovir exposures resulting from a 25-mg/kg dose were higher (C<span class="Sub">max</span>: â†‘30%, AUC: â†‘60%) than acyclovir exposures following a 1-gram dose of valacyclovir in adults. Acyclovir is not approved for suppressive therapy in infants and children following neonatal HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; therefore valacyclovir is not recommended for this indication because efficacy cannot be extrapolated from acyclovir.</p>
<p>Study 3 was a single-dose pharmacokinetic, multiple-dose safety study in 28Â pediatric patients aged 1 to less than 12Â years with clinically suspected HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. None of the children enrolled in this study had <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Each subject was dosed with valacyclovir oral suspension, 10Â mg/kg twice daily for 3 to 5Â days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. The mean projected daily acyclovir systemic exposures in pediatric patients across all age-groups (1 to less than 12Â years) were lower (C<span class="Sub">max</span>: â†“20%, AUC: â†“33%) compared with the acyclovir systemic exposures in adults receiving valacyclovir 500Â mg twice daily, but were higher (daily AUC: â†‘16%) than systemic exposures in adults receiving acyclovir 200Â mg 5Â times daily. Insufficient data are available to support valacyclovir for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in this age-group because clinical information on recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in young children is limited; therefore, extrapolating efficacy data from adults to this population is not possible. Moreover, valacyclovir has not been studied in children aged 1 to less than 12Â years with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_787a9b57-e930-491d-aabe-f4923f11f277"></a><a name="section-8.4"></a><p></p>
<p class="First">Of the total number of subjects in clinical studies of VALTREX, 906 were 65 and over, and 352 were 75 and over. In a clinical study of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, the duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>) was longer in patients 65 and older compared with younger adults. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events <span class="Italics">[see Dosage and Administration (2.4), Warnings and Precautions (5.2, 5.3), Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94f072de-fc2e-4962-9912-f1f676c73f90"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage reduction is recommended when administering VALTREX to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (2.4), Warnings and Precautions (5.2, 5.3)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_e9e1ee3e-e581-4ac0-b0ca-a2abacc76211"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Caution should be exercised to prevent inadvertent <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> <span class="Italics">[see Use in Specific Populations (8.5), (8.6)]</span>. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5Â mg/mL) is exceeded in the intratubular fluid. In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored <span class="Italics">[see Dosage and Administration (2.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_192c6354-e35e-47ff-8ba7-d7a29e67a957"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VALTREX (valacyclovir hydrochloride) is the hydrochloride salt of the <span class="Italics">L</span>-valyl ester of the antiviral drug acyclovir.</p>
<p>VALTREX Caplets are for oral administration. Each caplet contains valacyclovir hydrochloride equivalent to 500Â mg or 1Â gram valacyclovir and the inactive ingredients carnauba wax, colloidal silicon dioxide, crospovidone, FD&amp;C Blue No. 2 Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbateÂ 80, povidone, and titanium dioxide. The blue, film-coated caplets are printed with edible white ink.</p>
<p>The chemical name of valacyclovir hydrochloride is <span class="Italics">L</span>-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9<span class="Italics">H</span>-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula:</p>
<div class="Figure"><img alt="Valacyclovir hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b4450539-78ec-4e8a-8cfc-56dcde7984a0&amp;name=dc560f22-fda8-41ca-a869-dca459ebbcfe-01.jpg"></div>
<p>Valacyclovir hydrochloride is a white to off-white powder with the molecular formula C<span class="Sub">13</span>H<span class="Sub">20</span>N<span class="Sub">6</span>O<span class="Sub">4</span>â€¢HCl and a molecular weight of 360.80. The maximum solubility in water at 25Â°C is 174Â mg/mL. The pk<span class="Sub">a</span>s for valacyclovir hydrochloride are 1.90, 7.47, and 9.43.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_b950e345-99fd-48c2-8a8d-3a4ac4817290"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_431f62ad-eaf0-4fdb-83ef-bb6f7d0c12a0"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Valacyclovir is an antiviral drug <span class="Italics">[see Clinical Pharmacology (12.4)].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ad12d0c4-01fa-434b-ab5a-db18a8b0cbf5"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of valacyclovir and acyclovir after oral administration of VALTREX have been investigated in 14Â volunteer studies involving 283Â adults and in 3Â studies involving 112Â pediatric subjects aged 1Â month to less than 12Â years.</p>
<p><span class="Underline">Pharmacokinetics in Adults:</span><span class="Italics"> Absorption and Bioavailability: </span>After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and <span class="Italics">L-</span>valine by first-pass intestinal and/or hepatic metabolism.</p>
<p>The absolute bioavailability of acyclovir after administration of VALTREX is 54.5%Â Â±Â 9.1% as determined following a 1-gram oral dose of VALTREX and a 350Â mg intravenous acyclovir dose to 12Â healthy volunteers. Acyclovir bioavailability from the administration of VALTREX is not altered by administration with food (30Â minutes after an 873Â Kcal breakfast, which included 51Â grams of fat).</p>
<p>Acyclovir pharmacokinetic parameter estimates following administration of VALTREX to healthy adult volunteers are presented in Table 3. There was a less than dose-proportional increase in acyclovir maximum concentration (C<span class="Sub">max</span>) and area under the acyclovir concentration-time curve (AUC) after single-dose and multiple-dose administration (4Â times daily) of VALTREX from doses between 250Â mg to 1Â gram.</p>
<p>There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in adults with normal renal function.</p>
<a name="id_d857dd6a-8d14-4296-8718-8fbbd9a9d7a5"></a><table width="505.000">
<caption><span>Table 3. Mean (Â±SD) Plasma Acyclovir Pharmacokinetic Parameters Following Administration of VALTREX to Healthy Adult Volunteers</span></caption>
<col width="10.9%">
<col width="24.0%">
<col width="20.6%">
<col width="24.0%">
<col width="20.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Dose</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">
<p class="First">Single-Dose Administration</p>(NÂ =Â 8)</td>
<td class="Botrule" align="center" colspan="2" valign="bottom">
<p class="First">Multiple-Dose Administration<span class="Sup">a</span></p>(NÂ =Â 24, 8Â per treatment arm)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">C<span class="Sub">max</span> (Â±SD) </p>(mcg/mL)</td>
<td class="Botrule Rrule" align="center" valign="bottom">AUC (Â±SD) (hrâ—?mcg/mL)</td>
<td class="Botrule Rrule" align="center" valign="bottom">C<span class="Sub">max</span> (Â±SD) (mcg/mL)</td>
<td class="Botrule" align="center" valign="bottom">AUC (Â±SD) (hrâ—?mcg/mL)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="justify" valign="top">100Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">0.83 (Â±0.14)</td>
<td class="Botrule Rrule" align="center" valign="top">2.28 (Â±0.40)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
<td class="Botrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Rrule" align="justify" valign="top">250Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">2.15 (Â±0.50)</td>
<td class="Botrule Rrule" align="center" valign="top">5.76 (Â±0.60)</td>
<td class="Botrule Rrule" align="center" valign="top">2.11 (Â±0.33)</td>
<td class="Botrule" align="center" valign="top">5.66 (Â±1.09)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="justify" valign="top">500Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">3.28 (Â±0.83)</td>
<td class="Botrule Rrule" align="center" valign="top">11.59 (Â±1.79)</td>
<td class="Botrule Rrule" align="center" valign="top">3.69 (Â±0.87)</td>
<td class="Botrule" align="center" valign="top">9.88 (Â±2.01)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="justify" valign="top">750Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">4.17 (Â±1.14)</td>
<td class="Botrule Rrule" align="center" valign="top">14.11 (Â±3.54)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
<td class="Botrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Rrule" align="justify" valign="top">1,000Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">5.65 (Â±2.37)</td>
<td class="Botrule Rrule" align="center" valign="top">19.52 (Â±6.04)</td>
<td class="Botrule Rrule" align="center" valign="top">4.96 (Â±0.64)</td>
<td class="Botrule" align="center" valign="top">15.70 (Â±2.27)</td>
</tr>
<tr><td align="left" colspan="5" valign="top">
<span class="Sup">a</span> Administered 4Â times daily for 11Â days.</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top">ND = not done.</td></tr>
</tbody>
</table>
<p><span class="Italics">Distribution: </span>The binding of valacyclovir to human plasma proteins ranges from 13.5% to 17.9%. The binding of acyclovir to human plasma proteins ranges from 9% to 33%.</p>
<p><span class="Italics">Metabolism: </span>Valacyclovir is converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. Acyclovir is converted to a small extent to inactive metabolites by aldehyde oxidase and by alcohol and aldehyde dehydrogenase. Neither valacyclovir nor acyclovir is metabolized by cytochrome P450 enzymes. Plasma concentrations of unconverted valacyclovir are low and transient, generally becoming non-quantifiable by 3Â hours after administration. Peak plasma valacyclovir concentrations are generally less than 0.5Â mcg/mL at all doses. After single-dose administration of 1Â gram of VALTREX, average plasma valacyclovir concentrations observed were 0.5, 0.4, and 0.8Â mcg/mL in patients with hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and in healthy volunteers who received concomitant cimetidine and probenecid, respectively.</p>
<p><span class="Italics">Elimination: </span>The pharmacokinetic disposition of acyclovir delivered by valacyclovir is consistent with previous experience from intravenous and oral acyclovir. Following the oral administration of a single 1Â gram dose of radiolabeled valacyclovir to 4Â healthy subjects, 46% and 47% of administered radioactivity was recovered in urine and feces, respectively, over 96Â hours. Acyclovir accounted for 89% of the radioactivity excreted in the urine. Renal clearance of acyclovir following the administration of a single 1-gram dose of VALTREX to 12Â healthy volunteers was approximately 255Â Â±Â 86Â mL/min which represents 42% of total acyclovir apparent plasma clearance.</p>
<p>The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3Â hours in all studies of VALTREX in volunteers with normal renal function.</p>
<p><span class="Underline">Specific Populations:</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span>Reduction in dosage is recommended in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)].</span></p>
<p>Following administration of VALTREX to volunteers with ESRD, the average acyclovir half-life is approximately 14Â hours. During hemodialysis, the acyclovir half-life is approximately 4Â hours. Approximately one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session. Apparent plasma clearance of acyclovir in dialysis patients was 86.3Â Â±Â 21.3Â mL/min/1.73Â m<span class="Sup">2</span> compared with 679.16Â Â±Â 162.76Â mL/min/1.73Â m<span class="Sup">2</span> in healthy volunteers.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>Administration of VALTREX to patients with moderate (biopsy-proven cirrhosis) or severe (with and without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and biopsy-proven cirrhosis) liver disease indicated that the rate but not the extent of conversion of valacyclovir to acyclovir is reduced, and the acyclovir half-life is not affected. Dosage modification is not recommended for patients with cirrhosis.</p>
<p><span class="Italics">HIV-1 Disease: </span>In 9Â patients with HIV-1 disease and CD4+ cell counts less than 150Â cells/mm<span class="Sup">3</span> who received VALTREX at a dosage of 1Â gram 4Â times daily for 30Â days, the pharmacokinetics of valacyclovir and acyclovir were not different from that observed in healthy volunteers.</p>
<p><span class="Italics">Geriatrics: </span>After single-dose administration of 1Â gram of VALTREX in healthy geriatric volunteers, the half-life of acyclovir was 3.11Â Â±Â 0.51Â hours, compared with 2.91Â Â±Â 0.63Â hours in healthy younger adult volunteers. The pharmacokinetics of acyclovir following single- and multiple-dose oral administration of VALTREX in geriatric volunteers varied with renal function. Dose reduction may be required in geriatric patients, depending on the underlying renal status of the patient <span class="Italics">[see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)]</span>.</p>
<p><span class="Italics">Pediatrics: </span>Acyclovir pharmacokinetics have been evaluated in a total of 98Â pediatric patients (agedÂ 1 month to less than 12Â years) following administration of the first dose of an extemporaneous oral suspension of valacyclovir <span class="Italics">[see Adverse Reactions (6.2), Use in Specific Populations (8.4)]</span>. Acyclovir pharmacokinetic parameter estimates following a 20-mg/kg dose are provided in Table 4.</p>
<a name="id_7b19f6bf-e2c9-41bb-a1ca-ee2845f83adc"></a><table width="521.000">
<caption><span>Table 4. Mean (Â±SD) Plasma Acyclovir Pharmacokinetic Parameter Estimates Following First-Dose Administration of 20Â mg/kg Valacyclovir Oral Suspension to Pediatric Patients vs. 1-Gram Single Dose of VALTREX to Adults</span></caption>
<col width="17.9%">
<col width="19.0%">
<col width="19.0%">
<col width="20.0%">
<col width="24.2%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top">
<span class="Sup">a</span> Historical estimates using pediatric pharmacokinetic sampling schedule.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Parameter</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom">
<p class="First">Pediatric Patients</p>(20Â mg/kg Oral Suspension)</td>
<td class="Botrule" align="center" rowspan="2" valign="bottom">
<p class="First">Adults</p>
<p>1-gram Solid Dose of VALTREX<span class="Sup">a</span></p>(NÂ =Â 15)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">1 - &lt;2Â yr</p>(NÂ =Â 6)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">2 - &lt;6Â yr</p>(NÂ =Â 12)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">6 - &lt;12Â yr</p>(NÂ =Â 8)</td>
</tr>
<tr>
<td class="Rrule" align="justify" valign="middle">AUCÂ (mcgâ€¢hr/mL)</td>
<td class="Rrule" align="center" valign="middle">14.4 (Â±6.26)</td>
<td class="Rrule" align="center" valign="middle">10.1 (Â±3.35)</td>
<td class="Rrule" align="center" valign="middle">13.1 (Â±3.43)</td>
<td align="center" valign="middle">17.2 (Â±3.10)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="justify" valign="top">C<span class="Sub">max</span>Â (mcg/mL)</td>
<td class="Botrule Rrule" align="center" valign="middle">4.03 (Â±1.37)</td>
<td class="Botrule Rrule" align="center" valign="middle">3.75 (Â±1.14)</td>
<td class="Botrule Rrule" align="center" valign="middle">4.71 (Â±1.20)</td>
<td class="Botrule" align="center" valign="middle">4.72 (Â±1.37)</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Drug Interactions:</span> When VALTREX is coadministered with antacids, cimetidine and/or probenicid, digoxin, or thiazide diuretics in patients with normal renal function, the effects are not considered to be of clinical significance (see below). Therefore, when VALTREX is coadministered with these drugs in patients with normal renal function, no dosage adjustment is recommended.</p>
<p><span class="Italics">Antacids: </span>The pharmacokinetics of acyclovir after a single dose of VALTREX (1Â gram) were unchanged by coadministration of a single dose of antacids (Al<span class="Sup">3+</span> or Mg<span class="Sup">++</span>).</p>
<p><span class="Italics">Cimetidine: </span>Acyclovir C<span class="Sub">max</span> and AUC following a single dose of VALTREX (1Â gram) increased by 8% and 32%, respectively, after a single dose of cimetidine (800Â mg).</p>
<p><span class="Italics">Cimetidine Plus Probenecid: </span>Acyclovir C<span class="Sub">max</span> and AUC following a single dose of VALTREX (1Â gram) increased by 30% and 78%, respectively, after a combination of cimetidine and probenecid, primarily due to a reduction in renal clearance of acyclovir. </p>
<p><span class="Italics">Digoxin: </span>The pharmacokinetics of digoxin were not affected by coadministration of VALTREX 1Â gram 3Â times daily, and the pharmacokinetics of acyclovir after a single dose of VALTREX (1Â gram) was unchanged by coadministration of digoxin (2Â doses of 0.75Â mg).</p>
<p><span class="Italics">Probenecid: </span>Acyclovir C<span class="Sub">max</span> and AUC following a single dose of VALTREX (1Â gram) increased by 22% and 49%, respectively, after probenecid (1Â gram).</p>
<p><span class="Italics">Thiazide Diuretics: </span>The pharmacokinetics of acyclovir after a single dose of VALTREX (1Â gram) were unchanged by coadministration of multiple doses of thiazide diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_16ceb6c4-bda9-495e-9684-9fba95194b0a"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action:</span> Valacyclovir is a nucleoside analogue DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV both in cell culture and in vivo.</p>
<p>The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of herpes viral DNA. This is accomplished in 3Â ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK.</p>
<p><span class="Underline">Antiviral Activities:</span> The quantitative relationship between the cell culture susceptibility of herpesviruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (EC<span class="Sub">50</span>), vary greatly depending upon a number of factors. Using plaque-reduction assays, the EC<span class="Sub">50</span> values against herpes simplex virus isolates range from 0.09 to 60Â Î¼M (0.02 to 13.5Â mcg/mL) for HSV-1 and from 0.04 to 44Â Î¼M (0.01 to 9.9Â mcg/mL) for HSV-2. The EC<span class="Sub">50</span> values for acyclovir against most laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of VZV range from 0.53 to 48Â Î¼M (0.12 to 10.8Â mcg/mL). Acyclovir also demonstrates activity against the Oka vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of VZV with a mean EC<span class="Sub">50</span> of 6Â Î¼M (1.35Â mcg/mL).</p>
<p><span class="Underline">Resistance:</span> Resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of VZV with reduced susceptibility to acyclovir have been recovered from patients with AIDS. In these cases, TK-deficient mutants of VZV have been recovered.</p>
<p>Resistance of HSV and VZV to acyclovir occurs by the same mechanisms. While most of the acyclovir-resistant mutants isolated thus far from immunocompromised patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have also been isolated. TK-negative mutants may cause severe disease in immunocompromised patients. The possibility of viral resistance to valacyclovir (and therefore, to acyclovir) should be considered in patients who show poor clinical response during therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_eb8236f3-5fc8-435d-b5a1-49fbd22fb28e"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b60ef738-babd-4f3c-a10d-90e732fa8b6d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The data presented below include references to the steady-state acyclovir AUC observed in humans treated with 1Â gram VALTREX given orally 3Â times a day to treat <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir <span class="Italics">[see Clinical Pharmacology (12.3)].</span></p>
<p>Valacyclovir was noncarcinogenic in lifetime carcinogenicity bioassays at single daily doses (gavage) of valacyclovir giving plasma acyclovir concentrations equivalent to human levels in the mouse bioassay and 1.4 to 2.3Â times human levels in the rat bioassay. There was no significant difference in the incidence of tumors between treated and control animals, nor did valacyclovir shorten the latency of tumors.</p>
<p>Valacyclovir was tested in 5Â genetic toxicity assays. An Ames assay was negative in the absence or presence of metabolic activation. Also negative were an inÂ vitro cytogenetic study with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and a rat cytogenetic study.</p>
<p>In the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, valacyclovir was not mutagenic in the absence of metabolic activation. In the presence of metabolic activation (76% to 88% conversion to acyclovir), valacyclovir was mutagenic.</p>
<p>Valacyclovir was mutagenic in a mouse micronucleus assay.</p>
<p>Valacyclovir did not impair fertility or reproduction in rats at 6Â times human plasma levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_98c66a28-0263-4dda-84c5-bef0286f232e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4dfd0576-4dfb-4173-8b01-573f61a18d07"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</h2>
<p class="First">Two double-blind, placebo-controlled clinical trials were conducted in 1,856Â healthy adults and adolescents (aged greater than or equal to 12Â years) with a history of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. Patients self-initiated therapy at the earliest symptoms and prior to any signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore. The majority of patients initiated treatment within 2Â hours of onset of symptoms. Patients were randomized to VALTREX 2Â grams twice daily on DayÂ 1 followed by placebo on DayÂ 2, VALTREX 2Â grams twice daily on DayÂ 1 followed by 1Â gram twice daily on DayÂ 2, or placebo on DaysÂ 1 and 2.</p>
<p>The mean duration of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore episodes was about 1Â day shorter in treated subjects as compared with placebo. The 2-day regimen did not offer additional benefit over the 1-day regimen.</p>
<p>No significant difference was observed between subjects receiving VALTREX or placebo in the prevention of progression of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore lesions beyond the papular stage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0025b029-8234-44ac-b827-43e06a831cde"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Infections</h2>
<p class="First"><span class="Underline">Initial Episode:</span> Six hundred forty-three immunocompetent adults with first-episode <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> who presented within 72Â hours of symptom onset were randomized in a double-blind trial to receive 10Â days of VALTREX 1Â gram twice daily (nÂ =Â 323) or oral acyclovir 200Â mg 5Â times a day (nÂ =Â 320). For both treatment groups the median time to lesion healing was 9Â days, the median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was 5Â days, and the median time to cessation of viral shedding was 3Â days.</p>
<p><span class="Underline">Recurrent Episodes:</span> Three double-blind trials (2 of them placebo-controlled) in immunocompetent adults with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> were conducted. Patients self-initiated therapy within 24Â hours of the first sign or symptom of a recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episode.</p>
<p>In 1Â study, patients were randomized to receive 5Â days of treatment with either VALTREX 500Â mg twice daily (nÂ =Â 360) or placebo (nÂ =Â 259). The median time to lesion healing was 4Â days in the group receiving VALTREX 500Â mg versus 6Â days in the placebo group, and the median time to cessation of viral shedding in patients with at least 1Â positive culture (42% of the overall study population) was 2Â days in the group receiving VALTREX 500Â mg versus 4Â days in the placebo group. The median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was 3Â days in the group receiving VALTREX 500Â mg versus 4Â days in the placebo group. Results supporting efficacy were replicated in a second trial.</p>
<p>In a third study, patients were randomized to receive VALTREX 500Â mg twice daily for 5Â days (nÂ =Â 398) or VALTREX 500Â mg twice daily for 3Â days (and matching placebo twice daily for 2Â additional days) (nÂ =Â 402). The median time to lesion healing was about 4Â½Â days in both treatment groups. The median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was about 3Â days in both treatment groups.</p>
<p><span class="Underline">Suppressive Therapy:</span> Two clinical studies were conducted, one in immunocompetent adults and one in HIV-1-infected adults.</p>
<p>A double-blind, 12-month, placebo- and active-controlled study enrolled immunocompetent adults with a history of 6Â or more recurrences per year. Outcomes for the overall study population are shown in TableÂ 5.</p>
<a name="id_d1c5acdf-679c-44f4-9cee-3be053729c50"></a><table width="588.000">
<caption><span>Table 5. Recurrence Rates in Immunocompetent Adults at 6 and 12 Months</span></caption>
<col width="30.8%">
<col width="11.2%">
<col width="15.0%">
<col width="5.6%">
<col width="11.2%">
<col width="20.6%">
<col width="5.6%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="7" valign="top">
<span class="Sup">a</span> Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Outcome</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">6Â Months</td>
<td class="Botrule" align="center" colspan="3" valign="top">12Â Months</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX </p>
<p>1Â gram </p>
<p>once daily</p>(nÂ =Â 269)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Oral acyclovir</p>
<p>400Â mg </p>
<p>twice daily</p>(nÂ =Â 267)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 134)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX</p>
<p>1Â gram once daily</p>(nÂ =Â 269)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Oral acyclovir </p>
<p>400Â mg </p>
<p>twice daily</p>(nÂ =Â 267)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 134)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Recurrence free</td>
<td class="Rrule" align="center" valign="top">55%</td>
<td class="Rrule" align="center" valign="top">54%</td>
<td class="Rrule" align="center" valign="top">7%</td>
<td class="Rrule" align="center" valign="top">34%</td>
<td class="Rrule" align="center" valign="top">34%</td>
<td align="center" valign="top">4%</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Recurrences</td>
<td class="Rrule" align="center" valign="top">35%</td>
<td class="Rrule" align="center" valign="top">36%</td>
<td class="Rrule" align="center" valign="top">83%</td>
<td class="Rrule" align="center" valign="top">46%</td>
<td class="Rrule" align="center" valign="top">46%</td>
<td align="center" valign="top">85%</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Unknown<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10%</td>
<td class="Botrule Rrule" align="center" valign="top">10%</td>
<td class="Botrule Rrule" align="center" valign="top">10%</td>
<td class="Botrule Rrule" align="center" valign="top">19%</td>
<td class="Botrule Rrule" align="center" valign="top">19%</td>
<td class="Botrule" align="center" valign="top">10%</td>
</tr>
</tbody>
</table>
<p>Subjects with 9 or fewer recurrences per year showed comparable results with VALTREX 500Â mg once daily.</p>
<p>In a second study, 293Â HIV-1-infected adults on stable antiretroviral therapy with a history of 4 or more recurrences of ano-<span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> per year were randomized to receive either VALTREX 500Â mg twice daily (nÂ =Â 194) or matching placebo (nÂ =Â 99) for 6Â months. The median duration of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in enrolled subjects was 8Â years, and the median number of recurrences in the year prior to enrollment was 5. Overall, the median prestudy HIV-1 RNA was 2.6Â log<span class="Sub">10</span>Â copies/mL. Among patients who received VALTREX, the prestudy median CD4+ cell count was 336Â cells/mm<span class="Sup">3</span>; 11% had less than 100Â cells/mm<span class="Sup">3</span>, 16% had 100 to 199Â cells/mm<span class="Sup">3</span>, 42% had 200 to 499Â cells/mm<span class="Sup">3</span>, and 31% had greater than or equal to 500Â cells/mm<span class="Sup">3</span>. Outcomes for the overall study population are shown in TableÂ 6.</p>
<a name="id_d6833ecf-bb1f-48b7-9c22-327f9f7c6b19"></a><table width="445.000">
<caption><span>Table 6. Recurrence Rates in HIV-1-Infected Adults at 6 Months</span></caption>
<col width="33.3%">
<col width="36.0%">
<col width="30.8%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">
<span class="Sup">a</span> Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="bottom">Outcome</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX </p>
<p>500Â mg twice daily</p>(nÂ =Â 194)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 99)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Recurrence free </td>
<td class="Rrule" align="center" valign="top">65%</td>
<td align="center" valign="top">26%</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Recurrences</td>
<td class="Rrule" align="center" valign="top">17%</td>
<td align="center" valign="top">57%</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Unknown<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18%</td>
<td class="Botrule" align="center" valign="top">17%</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Reduction of Transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span> A double-blind, placebo-controlled study to assess transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> was conducted in 1,484 monogamous, heterosexual, immunocompetent adult couples. The couples were discordant for HSV-2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The source partner had a history of 9 or fewer <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episodes per year. Both partners were counseled on safer sex practices and were advised to use condoms throughout the study period. Source partners were randomized to treatment with either VALTREX 500Â mg once daily or placebo once daily for 8Â months. The primary efficacy endpoint was symptomatic acquisition of HSV-2 in susceptible partners. Overall HSV-2 acquisition was defined as symptomatic HSV-2 acquisition and/or HSV-2 seroconversion in susceptible partners. The efficacy results are summarized in Table 7.</p>
<a name="id_797530d6-051b-46d0-beac-ebb6fc0d77c9"></a><table width="461.000">
<caption><span>Table 7. Percentage of Susceptible Partners Who Acquired HSV-2 Defined by the Primary and Selected Secondary Endpoints</span></caption>
<col width="51.2%">
<col width="23.9%">
<col width="24.9%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">
<span class="Sup">a</span> Results show reductions in risk of 75% (symptomatic HSV-2 acquisition), 50% (HSV-2 seroconversion), and 48% (overall HSV-2 acquisition) with VALTREX versus placebo. Individual results may vary based on consistency of safer sex practices.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="bottom">Endpoint</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">VALTREX<span class="Sup">a</span></p>(nÂ =Â 743)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">Placebo</p>(nÂ =Â 741)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Symptomatic HSV-2 acquisition</td>
<td class="Botrule Rrule" align="center" valign="top">4 (0.5%)</td>
<td class="Botrule" align="center" valign="top">16 (2.2%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">HSV-2 seroconversion</td>
<td class="Botrule Rrule" align="center" valign="top">12 (1.6%)</td>
<td class="Botrule" align="center" valign="top">24 (3.2%)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Overall HSV-2 acquisition</td>
<td class="Botrule Rrule" align="center" valign="top">14 (1.9%)</td>
<td class="Botrule" align="center" valign="top">27 (3.6%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f48a819-58ed-4c71-a5ab-737e0bafe10e"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></h2>
<p class="First">Two randomized double-blind clinical trials in immunocompetent adults with localized <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> were conducted. VALTREX was compared with placebo in patients aged less than 50Â years, and with oral acyclovir in patients aged greater than 50Â years. All patients were treated within 72Â hours of appearance of zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In patients aged less than 50Â years, the median time to cessation of new lesion formation was 2Â days for those treated with VALTREX compared with 3Â days for those treated with placebo. In patients aged greater than 50Â years, the median time to cessation of new lesions was 3Â days in patients treated with either VALTREX or oral acyclovir. In patients aged less than 50Â years, no difference was found with respect to the duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>) between the recipients of VALTREX and placebo. In patients aged greater than 50Â years, among the 83% who reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>), the median duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing [95% confidence interval] in days was: 40 [31, 51], 43 [36, 55], and 59 [41, 77] for 7-day VALTREX, 14-day VALTREX, and 7-day oral acyclovir, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6514e2a-b23f-4dda-9c06-75f0660e6b8e"></a><a name="section-13.4"></a><p></p>
<h2>14.4 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></h2>
<p class="First">The use of VALTREX for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients aged 2 to less than 18Â years is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by safety and extrapolated efficacy data from 3Â randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients.</p>
<p> The single-dose pharmacokinetic and multiple-dose safety study enrolled 27Â pediatric patients aged 1 to less than 12Â years with clinically suspected VZV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Each subject was dosed with valacyclovir oral suspension, 20Â mg/kg 3Â times daily for 5Â days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. The mean projected daily acyclovir exposures in pediatric patients across all age-groups (1 to less than 12Â years) were lower (C<span class="Sub">max</span>: â†“13%, AUC: â†“30%) than the mean daily historical exposures in adults receiving valacyclovir 1Â gram 3Â times daily, but were higher (daily AUC: â†‘50%) than the mean daily historical exposures in adults receiving acyclovir 800Â mg 5Â times daily. The projected daily exposures in pediatric patients were greater (daily AUC approximately 100% greater) than the exposures seen in immunocompetent pediatric patients receiving acyclovir 20Â mg/kg 4Â times daily for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. Based on the pharmacokinetic and safety data from this study and the safety and extrapolated efficacy data from the acyclovir studies, oral valacyclovir 20Â mg/kg 3Â times a day for 5Â days (not to exceed 1Â gram 3Â times daily) is recommended for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients aged 2 to less than 18Â years. Because the efficacy and safety of acyclovir for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in children aged less than 2Â years have not been established, efficacy data cannot be extrapolated to support valacyclovir treatment in children aged less than 2Â years with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. Valacyclovir is also not recommended for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> in children because safety data up to 7Â daysâ€™ duration are not available <span class="Italics">[see Use in Specific Populations (8.4)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bf38df10-918c-4c77-b7e4-833e3aac9300"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<br><p class="First">VALTREX Caplets (blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides) containing valacyclovir hydrochloride equivalent to 1Â gram valacyclovir and printed with "VALTREX 1Â gram."</p>
<a name="i10e2dec0-4a02-4bc9-84ec-58c19eed1a4b"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 03<br>
</td>
<td>NDC 54868-3993-8<br>
</td>
</tr>
<tr>
<td>Bottles of 10<br>
</td>
<td>NDC 54868-3993-1<br>
</td>
</tr>
<tr>
<td>Bottles of 15<br>
</td>
<td>NDC 54868-3993-0<br>
</td>
</tr>
<tr>
<td>Bottles of 20<br>
</td>
<td>NDC 54868-3993-5<br>
</td>
</tr>
<tr>
<td>Bottles of 21<br>
</td>
<td>NDC 54868-3993-2<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-3993-6<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Storage:</span></p>
<p>Store at 15Â° to 25Â°C (59Â° to 77Â°F). Dispense in a well-closed container as defined in the USP.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_341dc59e-273d-4922-b6ab-f7f9a33df18f"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6260ff62-e873-4caf-9383-4f6b96a266f9"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Importance of Adequate Hydration</h2>
<p class="First">Patients should be advised to maintain adequate hydration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc1db71c-6db0-464d-b069-3e411c6fb7ad"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</h2>
<p class="First">Patients should be advised to initiate treatment at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning). There are no data on the effectiveness of treatment initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>). Patients should be instructed that treatment for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> should not exceed 1Â day (2Â doses) and that their doses should be taken about 12Â hours apart. Patients should be informed that VALTREX is not a cure for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4225f437-8956-4c81-b678-e7b9943dbafd"></a><a name="section-15.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></h2>
<p class="First">Patients should be informed that VALTREX is not a cure for <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Because <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span> is frequently transmitted in the absence of symptoms through asymptomatic viral shedding. Therefore, patients should be counseled to use safer sex practices in combination with suppressive therapy with VALTREX. Sex partners of infected persons should be advised that they might be infected even if they have no symptoms. Type-specific serologic testing of asymptomatic partners of persons with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> can determine whether risk for HSV-2 acquisition exists.</p>
<p>VALTREX has not been shown to reduce transmission of sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than HSV-2.</p>
<p>If medical management of a <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode.</p>
<p>There are no data on the effectiveness of treatment initiated more than 72Â hours after the onset of signs and symptoms of a first episode of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> or more than 24Â hours after the onset of signs and symptoms of a recurrent episode.</p>
<p>There are no data on the safety or effectiveness of chronic suppressive therapy of more than 1Â yearâ€™s duration in otherwise healthy patients. There are no data on the safety or effectiveness of chronic suppressive therapy of more than 6Â monthsâ€™ duration in HIV-1 infected patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2941dd30-22cb-4aba-8b60-042a97dd28ef"></a><a name="section-15.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></h2>
<p class="First">There are no data on treatment initiated more than 72Â hours after onset of the zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Patients should be advised to initiate treatment as soon as possible after a diagnosis of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fffa877a-814c-4b56-87b2-786edae818ef"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></h2>
<p class="First">Patients should be advised to initiate treatment at the earliest sign or symptom of</p>
<p><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>.</p>
<p>Distributed by:<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709</p>
<p>Manufactured by:<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709<br>or<br>DSM Pharmaceuticals, Inc.<br>Greenville, NC 27834</p>
<p>Â©2011, GlaxoSmithKline. All rights reserved.</p>
<p>October 2011</p>
<p>VTX:4PI</p>
<br><p><span class="Bold">Distributed and Repackaged by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â  74146<br></p>
<p><br></p>
<p>PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</p>
<p>_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ </p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_fa87a988-6f40-4a8c-8274-2a27fd65feac"></a><a name="section-16"></a><p></p>
<p class="First">Patient Information</p>
<p><span class="Bold">VALTREX<span class="Sup">Â®</span> (VAL-trex)</span></p>
<p><span class="Bold">(valacyclovir hydrochloride) Caplets</span></p>
<p>Read the Patient Information that comes with VALTREX before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Ask your healthcare provider or pharmacist if you have questions.</p>
<p><span class="Bold"><span class="Underline">What is VALTREX?</span></span></p>
<p>VALTREX is a prescription antiviral medicine. VALTREX lowers the ability of herpes viruses to multiply in your body.</p>
<p>VALTREX is used in adults:</p>
<ul>
<li>to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (also called <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">fever blisters</span> or <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>)</li>
<li>to treat <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> (also called <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>)</li>
<li>to treat or control <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> outbreaks in adults with normal immune systems</li>
<li>to control <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> outbreaks in adults infected with the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) with CD4+ cell count greater than 100Â cells/mm<span class="Sup">3</span>
</li>
<li>with safer sex practices to lower the chances of spreading <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to others. Even with safer sex practices, it is still possible to spread <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
</ul>
<p>VALTREX used daily with the following safer sex practices can lower the chances of passing <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to your partner.</p>
<ul>
<li><span class="Bold">Do not have sexual contact with your partner when you have any symptom or outbreak of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</span></li>
<li>
<span class="Bold">Use a condom </span>made of latex or polyurethane whenever you have sexual contact.</li>
</ul>
<p>VALTREX is used in children:</p>
<ul>
<li>to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (for children aged greater than or equal to 12Â years)</li>
<li>to treat <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> (for children aged 2 to less than 18Â years).<p class="First"></p>
</li>
</ul>
<p><span class="Bold">VALTREX does not cure <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span></span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>).</p>
<p>The efficacy of VALTREX has not been studied in children who have not reached puberty.</p>
<p><span class="Bold"><span class="Underline">What are <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, and <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>?</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold sores</span></span> are caused by a herpes virus that may be spread by kissing or other physical contact with the infected area of the skin. They are small, painful <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> that you get in or around your mouth. It is not known if VALTREX can stop the spread of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> to others.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> </span>is caused by a herpes virus. It causes an <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of multiple small, red bumps that look like pimples or insect bites usually appearing first on the abdomen or back and face. It can spread to almost everywhere else on the body and may be accompanied by flu-like symptoms.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span></span> is caused by the same herpes virus that causes <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. It causes small, painful <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> that happen on your skin. <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span> occurs in people who have already had <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span> can be spread to people who have not had <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or the <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> vaccine by contact with the infected areas of the skin. It is not known if VALTREX can stop the spread of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> to others.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span></span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>. It causes small, painful <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on your genital area. You can spread <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to others, even when you have no symptoms. If you are sexually active, you can still pass herpes to your partner, even if you are taking VALTREX. VALTREX, taken every day as prescribed and used with the following <span class="Bold">safer sex practices</span>, can lower the chances of passing <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to your partner.</p>
<ul>
<li>Do not have sexual contact with your partner when you have any symptom or outbreak of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
<li>Use a condom made of latex or polyurethane whenever you have sexual contact.</li>
</ul>
<p>Ask your healthcare provider for more information about safer sex practices.</p>
<p><span class="Bold"><span class="Underline">Who should not take VALTREX?</span></span></p>
<p><span class="Bold">Do not take VALTREX</span> if you are allergic to any of its ingredients or to acyclovir. The active ingredient is valacyclovir. See the end of this leaflet for a complete list of ingredients in VALTREX.</p>
<p><span class="Bold"><span class="Underline">Before taking VALTREX, tell your healthcare provider</span>:</span></p>
<p><span class="Bold">About all your medical conditions,</span> including:</p>
<ul>
<li>
<span class="Bold">if you have had a bone marrow transplant or kidney transplant, or if you have advanced HIV-1 disease or "AIDS".</span> Patients with these conditions may have a higher chance for getting a <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> called <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS). TTP/HUS can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>
<span class="Bold">if you have kidney problems.</span> Patients with kidney problems may have a higher chance for getting side effects or more kidney problems with VALTREX. Your healthcare provider may give you a lower dose of VALTREX.</li>
<li>
<span class="Bold">if you are aged 65Â years or older.</span> Elderly patients have a higher chance of certain side effects. Also, elderly patients are more likely to have kidney problems. Your healthcare provider may give you a lower dose of VALTREX.</li>
<li>
<span class="Bold">if you are pregnant or planning to become pregnant.</span> Talk with your healthcare provider about the risks and benefits of taking prescription drugs (including VALTREX) during pregnancy.</li>
<li>
<span class="Bold">if you are breastfeeding.</span> VALTREX may pass into your milk and it may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking VALTREX.</li>
<li>
<span class="Bold">about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. VALTREX may affect other medicines, and other medicines may affect VALTREX. It is a good idea to keep a complete list of all the medicines you take. Show this list to your healthcare provider and pharmacist any time you get a new medicine.</li>
</ul>
<p><span class="Bold"><span class="Underline">How should I take VALTREX?</span></span></p>
<p>Take VALTREX exactly as prescribed by your healthcare provider. Your dose of VALTREX and length of treatment will depend on the type of <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infection</span> that you have and any other medical problems that you have.</p>
<ul>
<li>Do not stop VALTREX or change your treatment without talking to your healthcare provider.</li>
<li>VALTREX can be taken with or without food.</li>
<li>If you are taking VALTREX to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, you should start treatment as soon as possible after your symptoms start. VALTREX may not help you if you start treatment too late.</li>
<li>If you miss a dose of VALTREX, take it as soon as you remember and then take your next dose at its regular time. However, if it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the regular time.</li>
<li>Do not take more than the prescribed number of VALTREX Caplets each day. Call your healthcare provider right away if you take too much VALTREX.</li>
</ul>
<p><span class="Bold"><span class="Underline">What are the possible side effects of VALTREX?</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> and nervous system problems are not common, but can be serious in some patients taking VALTREX. </span>Nervous system problemsÂ  includeÂ  <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, unsteady movement, shaky movements, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, speech problems, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are really not there), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> and nervous system problems have happened in patients who already have kidney disease and in elderly patients whose kidneys do not work well due to age. <span class="Bold">Always tell your healthcare provider if you have kidney problems before taking VALTREX. Call your doctor right away if you get a nervous system problem while you are taking VALTREX.</span></p>
<p>Common side effects of VALTREX in adults include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Side effects in HIV-1-infected adults include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. These side effects usually are mild and do not cause patients to stop taking VALTREX.</p>
<p>Other less common side effects in adults include painful periods in women, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, low blood cell counts, and changes in tests that measure how well the liver and kidneys work.</p>
<p>The most common side effect seen in children aged less than 18Â years was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Bold">Talk to your healthcare provider if you develop any side effects that concern you.</span></p>
<p>These are not all the side effects of VALTREX. For more information ask your healthcare provider or pharmacist.</p>
<p><span class="Bold"><span class="Underline">How should I store VALTREX?</span></span></p>
<ul>
<li>Store VALTREX Caplets at room temperature, 59Â° to 77Â°F (15Â° to 25Â°C).</li>
<li>Store VALTREX suspension between 2Â° to 8Â°C (36Â° to 46Â°F) in a refrigerator. Discard after 28Â days.</li>
<li>Keep VALTREX in a tightly closed container.</li>
<li>Do not keep medicine that is out of date or that you no longer need.</li>
<li>Keep VALTREX and all medicines out of the reach of children.</li>
</ul>
<p><span class="Bold"><span class="Underline">General information about VALTREX</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use VALTREX for a condition for which it was not prescribed. Do not give VALTREX to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about VALTREX. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about VALTREX that is written for health professionals. More information is available at www.VALTREX.com.</p>
<p><span class="Bold"><span class="Underline">What are the ingredients in VALTREX?</span></span></p>
<p><span class="Bold">Active Ingredient: </span>valacyclovir hydrochloride</p>
<p><span class="Bold">Inactive Ingredients:</span> carnauba wax, colloidal silicon dioxide, crospovidone, FD&amp;C Blue No. 2 Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, and titanium dioxide.</p>
<p>Distributed by:<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709</p>
<p>Manufactured by:<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709<br>or<br>DSM Pharmaceuticals, Inc.<br>Greenville, NC 27834</p>
<p>Â©2011, GlaxoSmithKline. All rights reserved.</p>
<p>October 2011</p>
<p>VTX:3PIL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_19137c9d-0758-46c8-8edc-4582f980cd13"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">VALTREX<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(valacyclovir HCl) CAPLETS</span></p>
<p><span class="Bold">500 mg </span></p>
<p>R<span class="Sub">x</span> only</p>
<div class="Figure"><img alt="no label available for 500 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b4450539-78ec-4e8a-8cfc-56dcde7984a0&amp;name=No%20Label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_56f8480d-be22-4e19-9bc8-c5e26bac3f8f"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><br></p>
<p><span class="Bold">VALTREX<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(valacyclovir HCl) CAPLETS</span></p>
<p><span class="Bold">1 gram </span></p>
<p>R<span class="Sub">x</span> only</p>
<p><br></p>
<p>Equivalent to 1 gram valacyclovir per caplet. </p>
<p>See prescribing information for Dosage and Administration.</p>
<p>Store at 15<span class="Sup">o</span> to 25<span class="Sup">o</span>C (59<span class="Sup">o</span> to 77<span class="Sup">o</span>F).</p>
<p>Do not use if printed safety seal under cap is broken or missing.</p>
<div class="Figure"><img alt="1 gram label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b4450539-78ec-4e8a-8cfc-56dcde7984a0&amp;name=3993.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALTREXÂ 		
					</strong><br><span class="contentTableReg">valacyclovir hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3804(NDC:0173-0933)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALACYCLOVIR HYDROCHLORIDE</strong> (ACYCLOVIR) </td>
<td class="formItem">VALACYCLOVIR</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VALTREX;500;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3804-0</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3804-2</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-3804-3</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-3804-4</td>
<td class="formItem">6  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-3804-5</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-3804-6</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020487</td>
<td class="formItem">07/08/1996</td>
<td class="formItem">06/30/2010</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALTREXÂ 		
					</strong><br><span class="contentTableReg">valacyclovir hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3993(NDC:0173-0565)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALACYCLOVIR HYDROCHLORIDE</strong> (ACYCLOVIR) </td>
<td class="formItem">VALACYCLOVIR</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VALTREX;1;gram</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3993-0</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3993-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-3993-2</td>
<td class="formItem">21  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-3993-5</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-3993-6</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-3993-8</td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020487</td>
<td class="formItem">04/25/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-3804, 54868-3993), repack(54868-3804, 54868-3993)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c22fa6a5-8dce-49ea-8512-0bffb3e6fcd9</div>
<div>Set id: b4450539-78ec-4e8a-8cfc-56dcde7984a0</div>
<div>Version: 2</div>
<div>Effective Time: 20120904</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
